



rejuveron

Age Better, Live Longer


our vision



Rejuveron's vision is to deliver innovation that will help people to live longer, healthier lives.

rejuveron life sciences


is a clinical stage biotechnology company developing therapies and technologies to tackle diseases of aging and prolong health span and life span for everyone



Develop novel therapies for age-related diseases

We combine knowledge of aging biology pathways with chronic disease mechanisms to attack the root causes of aging

Problem = aging
aging is the no. 1 risk factor for chronic diseases, leading to disability, mortality, reduced healthspan, and lifespan.



Expand to aging market
We will expand our therapies to treat the entire aging population to increase healthspan and lifespan.

PROBLEM

STRATEGY

SOLUTION

Age better, live longer

We combined this strategy with:

1. Accelerated drug discovery process using proprietary A.I. to rapidly design and develop novel molecules
2. Diversification via modality, stage, and aging biology hallmarks
3. A decentralised drug development framework that allows scientific founders to make new scientific discoveries in an entrepreneurial manner, while being guided by Rejuvenon's translational tools and experts to de-risk and optimise each stage of pre/clinical development.



BOARD OF DIRECTORS

LEADERSHIP



Christian Angermayer

Co-founder and Chairman of the Board



- Serial entrepreneur and investor
- Among many others, co-founder of ATAI Life Sciences and Ribopharma (today Alnylam, \$15bn market cap)
- Raised €1.5bn+ over last 20 years for portfolio companies
- Invests across entire lifecycle of company & has been involved in 40+ successful



Aaron Weaver CFA

Executive Chairman a.i.



- Former corporate lawyer and investment banker
- Experience in capital raising, legal and financial structuring, IPO preparations
- Strong ties to the investing community, experienced VC and biotech investor
- Key experience as one ATAI's earliest employee



Aksana Labokha PhD

Chief Executive Officer



- 10 years of experience in drug discovery within the pharmaceutical industry, including Venture Capital investments in multiple geographies
- Ph.D. in Biochemistry that was carried out jointly at the University of Heidelberg and the University of Göttingen



George Pavey CFA

Chief Financial Officer a.i.



- 20+ years as an investment banker at Credit Suisse and UBS.
- Various leadership positions in key financial centers including New York, London and Hong Kong.
- 100+ IPOs concluded (of which several biotech companies) and more than \$500 billion in capital raised
- Former CFO at a biotech company where he led the crossover financing round and listing effort.



Stephen Helliwell PhD

VP Discovery Biology



- More than 16 years pharma experience
- Established mitochondrial /longevity program at Novartis
- Strong track record in initiating and managing academic collaborations
- Seasoned global project team leader



Pierre-Antoine Mudry

Head of Investor Relations & Corporate Finance



- Eight years of experience in investment banking and financial markets
- Strategic coverage of the largest Swiss private banks and family offices
- Strong track record in investor relations and capital raising



Karim Allam

Chief Legal & People Officer



- More than 20 years of experience advising and counseling public and private companies in the biopharmaceutical industry.
- Strong track record in guiding and executing major transactions
- Key experience in establishing legal and compliance departments




○ senescence therapeutics

○ telomere therapeutics



○ vascular therapeutics

Endogenous stem cell regeneration

Problem: as we age, the regenerative capacity of the stem cells in our body decreases



Strategy: we discover and develop drugs that regulate stem cell and progenitor cells to repair and regenerate organs and tissues



Currently in Phase 1/2a in
retinitis pigmentosa
patients

Slowing muscle degeneration

Problem: as we age, we lose skeletal muscle strength and mass. This poses risk of physical disability, poor quality of life and premature death




Strategy: we have developed a novel drug combination for acute and age-dependent sarcopenia and will expand this therapy to further age-related indications following a successful Proof of Concept trial.

Opa1^{-/-} mice

21 weeks treated for 11 weeks


Running time, min




Currently in Phase 1b
 in acute sarcopenia

Removal of senescent cells

Problem: tumor cells become senescent to escape standard of care chemotherapy




Strategy: co-treatment of our anti-senescent mAb with current Standard of Care for solid tumors will improve response rate and efficacy



Normal cell


Tumor cell

Senescent cell




Restoring telomeres

Problem: telomeres shorten with each cell division as we age, leading to cellular dysfunction. Telomere length determines cellular replicative capacity



Strategy: we aim to restore prematurely damaged or shortened telomeres via a novel mechanism of action




Healthy humans have telomeres ranging between 10 and 20 kb.

Patient cells have much shorter telomeres

Deletion of negative regulator extends telomeres in these patient cells


Preventing neurodegeneration

Problem: Cerebral blood vessels become leaky with aging, causing neuroinflammation and cognitive decline



From Senatorov *et al.*, *Sci Trans. Med.* 2019

Strategy: we are creating a small molecule to improve blood brain barrier integrity in multiple age-related neurodegenerative indications – reversing the effects of aging.



Aging-regulated genes in brain ECs



- 1 We are a biotech company focusing on curing the **Diseases of Aging** to enable humans to **age better & live longer**
- 2 Our decentralised drug development framework is geared for entrepreneurial outcomes, with a **clinical translational expertise** accompanying **world class scientific and industry advisors**
- 3 We diversify via multiple programs and assets, each focusing on indications with high-unmet medical need, with **two advanced assets in clinical trials**
- 4 Rejuveron has **state-of-the-art laboratory** facilities and offices in Zürich's Bio-Technopark (Switzerland), with portfolio company activities in Canada, Spain and Belgium



Age Better, Live Longer



rejuveron

Questions?



stephen helliwell
vice president discovery biology
stephen@rejuveron.com